Comparison Between Free Gingival Graft and Palatal Pedicle Flap (Pedicle)

February 7, 2025 updated by: Chang Gung Memorial Hospital

Comparison of Keratinized Mucosa Width Increase Around Implants Between Palatal Pedicle Flap and Free Gingival Graft: a Clinical Controlled Trial

Patients requiring KMW gain(mm) during uncovering surgery were included. Two surgical methods were compared: apically position flap with free gingival graft (FGG group) and the palatal pedicle flap with collagen matrix (PPF group). The primary outcomes were KMW amount(mm) and shrinkage rate(%) at 2 weeks (2W) and 2 months (2M), 3 months (3ML), and 6 months after loading (6ML). Secondary outcomes included the intra- and inter- group comparison in mucosal recession (REC, mm), probing pocket depth (PPD, mm), marginal bone level (MBL, mm) and restoration designs.

Study Overview

Detailed Description

The present prospective clinical controlled trial included patients with at least one implant requiring stage 2 surgery. All implant surgeries were performed by the same surgeon (CYL) from 2021 July to 2023 January. All included patients had to meet the following inclusion criteria:

  1. Patient had at least one bone-level 3i implant*: 3.25, 4, and 5 mm in diameter, 8.5, 10, and 11.5 mm in length, and primary stability with an insertion torque ≥ 20Ncm. All implants needed to be free of peri-implant disease.
  2. Informed consent had been obtained prior to implant uncovering.
  3. Insufficient keratinized mucosal width (KMW< 2mm) was observed
  4. Complete data, including both clinical and radiographic outcomes, was available
  5. The patient followed the supportive postimplant regimen for a 12-month loading period, indicating good compliance.

Patients were excluded from this project if they have one of the following conditions:

  1. Untreated periodontitis.
  2. Uncontrolled systemic disease, such as hypertension, diabetes, and heavy smokers (more than 10 pieces per day).
  3. History of radiation therapy on head and neck regions.
  4. Patient with pregnancy
  5. Patient had pathologic lesions around peri-implant mucosa
  6. Guided bone regeneration was needed concomitantly with soft tissue phenotype modification during uncovering surgery.

Following the revised version of Helsinki Declaration in 2013, the protocol of current trial was conducted and approved by institutional review board of Chang Gung memorial hospital (IRB: 202100738A3). The cohort study was performed in accordance with STROBE statement.

2.2 Clinical Procedures Under local anesthesia, either APF combined with FGG or PPF with xenogenic matrix was performed around implants for KMW enhancement, which was concomitant with uncovering surgery.

In APF + FGG technique, a split- thickness flap was prepared and apically positioned using 5-0 (PDS*II, Polydioxanone, ETHICON) or 6-0 (PROLENE, ETHICON) sutures for flap stabilization. To eliminate muscle and frenum attachment at recipient site, vestibuloplasty and a periosteal incision were performed. A 4 mm or 6 mm healing abutment was then screwed onto the implants. FGG was harvested from palate in a 7-8 mm width and trimmed to an even thickness of 1 to 1.5 mm. A resorbable hemostatic sponge (Spongostan, Ethicon, Johnson & Johnson) was placed at donor site for wound coverage. For graft fixation, a loop suture with 6-0 (PROLENE, ETHICON) was first placed at the center of recipient site, additional sutures were added to enhance stabilization.

For the PPF group, the palatal sliding flap was a modified version of modified roll technique, as described in previous cohort study. Unlike the original technique, the crestal incision was placed 5 mm palatally from the border of keratinized tissue to allow for KMW redistribution, and a partially split-thickness flap was harvested from palatal connective tissue graft (CTG). Following buccal pouch flap preparation, a slight APF was required in cases with limited vestibular depth. When the palatal pedicle CTG was rolled in buccal pouch flap, a loop suture with 6-0 (PROLENE, ETHICON) was used for flap stabilization. The exposed connective tissue bed or bone around the implants was covered with a dual- layered collagen matrix (Lyoplant®Onlay, Aesculap), and additional sutures were used for graft and flap fixation. The specific indications for the PPF technique were shown as below: (1) the total keratinized mucosa width should be more than 3 mm; (2) the vertical soft tissue height should be more than 2 mm at the time of the uncovering surgery.

Post-operative instructions were instructed individually, and the medications were prescribed (acetaminophen 500 mg, tid for 5 days; amoxicillin 375 mg, tid for 5 days) for pain and infection control during post-operative phase. Two weeks after surgery, sutures were removed, and surgical wounds were followed at recall visit 2 months later. The implant prosthesis was then restored by prosthodontic specialists. The clinical and radiographic data were collected at 3, 6, and 12 months after loading during a strict maintenance period, which involved a 3-month interval over the course of 12 months. According to the supportive strategy, routine coronal prophylaxis with ultrasonic device and titanium curettes was applied, and oral hygiene reinforcement with adequately interdental brush and superfloss was instructed at every visit.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan, 105
        • Taipei Chang Gung Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Patient had at least one bone-level 3i implant*: 3.25, 4, and 5 mm in diameter, 8.5, 10, and 11.5 mm in length, and primary stability with an insertion torque ≥ 20Ncm. All implants needed to be free of peri-implant disease.
  2. Informed consent had been obtained prior to implant uncovering.
  3. Insufficient keratinized mucosal width (KMW< 2mm) was observed
  4. Complete data, including both clinical and radiographic outcomes, was available
  5. The patient followed the supportive postimplant regimen for a 12-month loading period, indicating good compliance.

Exclusion Criteria:

  1. Untreated periodontitis.
  2. Uncontrolled systemic disease, such as hypertension, diabetes, and heavy smokers (more than 10 pieces per day).
  3. History of radiation therapy on head and neck regions.
  4. Patient with pregnancy
  5. Patient had pathologic lesions around peri-implant mucosa
  6. Guided bone regeneration was needed concomitantly with soft tissue phenotype modification during uncovering surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: FGG group
In APF + FGG technique, a split- thickness flap was prepared and apically positioned using 5-0 (PDS*II, Polydioxanone, ETHICON) or 6-0 (PROLENE, ETHICON) sutures for flap stabilization.
In APF + FGG technique, a split- thickness flap was prepared and apically positioned using 5-0 (PDS*II, Polydioxanone, ETHICON) or 6-0 (PROLENE, ETHICON) sutures for flap stabilization. To eliminate muscle and frenum attachment at recipient site, vestibuloplasty and a periosteal incision were performed. A 4 mm or 6 mm healing abutment was then screwed onto the implants. FGG was harvested from palate in a 7-8 mm width and trimmed to an even thickness of 1 to 1.5 mm. A resorbable hemostatic sponge (Spongostan, Ethicon, Johnson & Johnson) was placed at donor site for wound coverage. For graft fixation, a loop suture with 6-0 (PROLENE, ETHICON) was first placed at the center of recipient site, additional sutures were added to enhance stabilization.
Other Names:
  • free gingival graft
Active Comparator: Palatal pedicle flap with collagen matrix
For thepalatal pedicle flap with collagen matrix (PPF) group, the palatal sliding flap was a modified version of modified roll technique, the crestal incision was placed 5 mm palatally from the border of keratinized tissue to allow for KMW redistribution, and a partially split-thickness flap was harvested from palatal connective tissue graft (CTG).
For the PPF group, the palatal sliding flap was a modified version of modified roll technique, as described in previous cohort study. Unlike the original technique, the crestal incision was placed 5 mm palatally from the border of keratinized tissue to allow for KMW redistribution, and a partially split-thickness flap was harvested from palatal connective tissue graft (CTG). Following buccal pouch flap preparation, a slight APF was required in cases with limited vestibular depth. When the palatal pedicle CTG was rolled in buccal pouch flap, a loop suture with 6-0 (PROLENE, ETHICON) was used for flap stabilization.
Other Names:
  • palatal pedical flap

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Keratinized mucosal width amount(mm)
Time Frame: at 2 weeks (2W) and 2 months (2M), 3 months (3ML), and 6 months after loading (6ML)
Keratinized mucosal width amount(mm) was measured with periodontal probe from mucosal margin to mucosogingival junction
at 2 weeks (2W) and 2 months (2M), 3 months (3ML), and 6 months after loading (6ML)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mucosal recession (REC, mm)
Time Frame: at 2 months (2M), 3 months (3ML), and 6 months after loading (6ML)
The distance from abutment top to mucosal margin
at 2 months (2M), 3 months (3ML), and 6 months after loading (6ML)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Probing pocket depth (PPD, mm)
Time Frame: 2 months(2M), 3- and 6- month loading(3ML, 6ML)
the pocket depth was measured with periodontal probe at 6 points around the implants
2 months(2M), 3- and 6- month loading(3ML, 6ML)
Marginal bone level (MBL, mm)
Time Frame: 3-month and 6 month loading(3ML, 6ML)
The distance from bone-implant contact to platform of the implant was evaluated ion peri-apical film
3-month and 6 month loading(3ML, 6ML)
Emergence profile
Time Frame: 3- month loading
The 3 restoration categories with straight, concave and convex.
3- month loading
Emergence angle (degree)
Time Frame: 3- month loading
the angle between the profile and long axis of implant
3- month loading

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 27, 2021

Primary Completion (Actual)

June 23, 2022

Study Completion (Actual)

March 7, 2023

Study Registration Dates

First Submitted

January 19, 2025

First Submitted That Met QC Criteria

February 7, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 7, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The data that support the findings of this study are available from the corresponding author upon request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peri-implant Bone Level

Clinical Trials on APF + FGG

Subscribe